IMDRF To Strike Pre And Postmarket Balance In Plan That Mirrors EU And US Priorities
This article was originally published in Clinica
The International Medical Device Regulators’ Forum (IMDRF) will seek to ensure that its members strike the right balance between premarket and postmarket review activity, as part of ongoing efforts to improve innovation and access to medical devices.
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.